Why the study?
Do low-molecular-weight heparins improve outcomes compared to unfractionated heparin in patients with acute coronary syndromes?
Do low-molecular-weight heparins improve outcomes compared to unfractionated heparin in patients with acute coronary syndromes?
This review summarizes the clinical trials and economic evaluations of low-molecular-weight heparins for the management of acute coronary syndromes.
Consolidates LMWH trial and cost data in ACS; leaves open optimal selection versus UFH pending updated analyses.
Our understanding of the pathophysiology of acute coronary syndromes is evolving as the role of prognostic coagulation markers and the different effects unfractionated heparin and low-molecular-weight heparins have on these coagulation markers are investigated. The results of recent clinical trials of low-molecular-weight heparins in acute coronary syndromes are summarized, and an economic evaluation of enoxaparin for these indications is reviewed.
No takes yet. Share an insight, caveat, or question.
Sarah A. Spinler (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: